Alvotech (ALVOW)

Market Cap	3.43B
Revenue (ttm)	393.92M
Net Income (ttm)	-441.45M
Shares Out	280.79M
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	138.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,040
Open	2.340
Previous Close	2.180
Day's Range	2.130 - 2.340
52-Week Range	2.130 - 2.340
Beta	-0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 27, 2025

About ALVOW

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 999
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVOW
• Website: https://www.alvotech.com

Financial Performance

In 2023, Alvotech's revenue was $93.38 million, an increase of 9.84% compared to the previous year's $85.02 million. Losses were -$551.73 million, 7.43% more than in 2022.